RBC Life Sciences, Inc.
RBCL
$0.0001
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -28.06% | -21.47% | -6.18% | 11.05% | 13.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.06% | -21.47% | -6.18% | 11.05% | 13.18% |
| Cost of Revenue | -29.36% | -28.44% | -8.71% | -9.00% | -10.30% |
| Gross Profit | -27.08% | -15.10% | -4.18% | 33.62% | 41.05% |
| SG&A Expenses | -1.47% | -7.16% | 4.96% | 24.84% | 37.78% |
| Depreciation & Amortization | -19.27% | -0.46% | -20.97% | -2.62% | 26.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.72% | -17.25% | -1.11% | 7.23% | 12.01% |
| Operating Income | -1,367.82% | -1,019.88% | -57.78% | 71.70% | 43.68% |
| Income Before Tax | 653.69% | -3,842.53% | -54.12% | 67.29% | 38.86% |
| Income Tax Expenses | 941.89% | -618.83% | -77.32% | 88.32% | 196.52% |
| Earnings from Continuing Operations | 367.56% | -3,621.21% | -45.54% | 53.19% | 13.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 367.56% | -3,621.21% | -45.54% | 53.19% | 13.57% |
| EBIT | -1,367.82% | -1,019.88% | -57.78% | 71.70% | 43.68% |
| EBITDA | -1,325.72% | -184.78% | -88.18% | 124.55% | 851.72% |
| EPS Basic | 367.44% | -3,600.00% | -45.55% | 53.12% | 13.33% |
| Normalized Basic EPS | -1,026.83% | -3,780.00% | -54.17% | 67.33% | 38.68% |
| EPS Diluted | 349.17% | -3,600.00% | -46.37% | 57.29% | 6.98% |
| Normalized Diluted EPS | -1,026.83% | -3,780.00% | -54.17% | 67.33% | 38.68% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.21% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
